HCW Net Tangible Assets from 2010 to 2026
| HCWB Stock | USD 1.04 0.05 5.05% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 43 M | Current Value 45.2 M | Quarterly Volatility 26 M |
Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 838.9 K or Interest Expense of 1.4 M, as well as many indicators such as Price To Sales Ratio of 295, Dividend Yield of 0.0 or Days Sales Outstanding of 144. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
HCW | Net Tangible Assets | Build AI portfolio with HCW Stock |
Analyzing HCW Biologics's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing HCW Biologics's current valuation and future prospects.
Latest HCW Biologics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of HCW Biologics over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. HCW Biologics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HCW Biologics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
HCW Net Tangible Assets Regression Statistics
| Arithmetic Mean | 8,131,478 | |
| Coefficient Of Variation | 319.66 | |
| Mean Deviation | 23,873,835 | |
| Median | (9,676,294) | |
| Standard Deviation | 25,993,322 | |
| Sample Variance | 675.7T | |
| Range | 67.9M | |
| R-Value | 0.80 | |
| Mean Square Error | 257.8T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 4,125,244 | |
| Total Sum of Squares | 10810.4T |
HCW Net Tangible Assets History
About HCW Biologics Financial Statements
HCW Biologics stakeholders use historical fundamental indicators, such as HCW Biologics' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in HCW Biologics' assets and liabilities are reflected in the revenues and expenses on HCW Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 43 M | 45.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out the analysis of HCW Biologics Correlation against competitors. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (16.41) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.